Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

NCT01188785 is registered in ClinicalTrials.gov with Silenseed Ltd as lead sponsor.

NCT NCT01188785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01188785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Lead sponsor
Silenseed Ltd
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
December 31, 2013
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma